| 產(chǎn)品編號 | bs-6265R-APC |
| 英文名稱1 | Rabbit Anti-HEF1/APC Conjugated antibody |
| 中文名稱 | APC標記的蛋白激酶底物相關(guān)蛋白抗體 |
| 別 名 | CAS L; Cas like docking; Cas scaffolding protein family member 2; CAS-L; CAS2; CASL; CASL_HUMAN; CASS2; Crk associated substrate related protein; CRK-associated substrate-related protein; dJ49G10.2 (Enhancer of Filamentation 1 (HEF1)); Enhancer of filamentation 1; Enhancer of filamentation 1 p55; HEF 1; HEF1; NEDD 9; NEDD-9; NEDD9; NEDD9 protein; Neural cell expressed developmentally down regulated 9; Neural precursor cell expressed developmentally down regulated 9; Neural precursor cell expressed developmentally down-regulated protein 9; NY REN 12 antigen antibody p105; Protein NEDD9; Renal carcinoma antigen NY-REN-12. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細胞生物 免疫學(xué) 染色質(zhì)和核信號 信號轉(zhuǎn)導(dǎo) 細胞凋亡 激酶和磷酸酶 t-淋巴細胞 b-淋巴細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Dog, Pig, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 92kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human HEF1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Docking protein which plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion. May function in transmitting growth control signals between focal adhesions at the cell periphery and the mitotic spindle in response to adhesion or growth factor signals initiating cell proliferation. May play an important role in integrin beta-1 or B cell antigen receptor (BCR) mediated signaling in B- and T-cells. Integrin beta-1 stimulation leads to recruitment of various proteins including CRK, NCK and SHPTP2 to the tyrosine phosphorylated form. Function: Docking protein which plays a central coordinating role for tyrosine-kinase-based signaling related to cell adhesion. May function in transmitting growth control signals between focal adhesions at the cell periphery and the mitotic spindle in response to adhesion or growth factor signals initiating cell proliferation. May play an important role in integrin beta-1 or B cell antigen receptor (BCR) mediated signaling in B- and T-cells. Integrin beta-1 stimulation leads to recruitment of various proteins including CRK, NCK and SHPTP2 to the tyrosine phosphorylated form. Subunit: Interacts with BCAR3 and SH2D3C. Homodimer. Can heterodimerize with HLH proteins ID2, E12, E47 and also with p130cas. Forms complexes in vivo with related adhesion focal tyrosine kinase (RAFTK), adapter protein CRKL and LYN kinase. Interacts with MICAL and TXNL4/DIM1. Subcellular Location: Cytoplasm, cell cortex. Nucleus. Golgi apparatus. Cell projection, lamellipodium. Cytoplasm. Cell junction, focal adhesion. Note=Localizes to both the cell nucleus and the cell periphery and is differently localized in fibroblasts and epithelial cells. In fibroblasts is predominantly nuclear and in some cells is present in the Golgi apparatus. In epithelial cells localized predominantly in the cell periphery with particular concentration in lamellipodia but is also found in the nucleus. Isoforms p105 and p115 are predominantly cytoplasmic and associate with focal adhesions while p55 associates with mitotic spindle. Enhancer of filamentation 1 p55: Cytoplasm, cytoskeleton, spindle. Tissue Specificity: Widely expressed. Higher levels detected in kidney, lung, and placenta. Also detected in T-cells, B-cells and diverse cell lines. The protein has been detected in lymphocytes, in diverse cell lines, and in lung tissues. Post-translational modifications: Cell cycle-regulated processing produces four isoforms: p115,p105, p65, and p55. Isoform p115 arises from p105 phosphorylationand appears later in the cell cycle. Isoform p55 arises from p105as a result of cleavage at a caspase cleavage-related site and itappears specifically at mitosis. The p65 isoform is poorlydetected. Focal adhesion kinase 1 phosphorylates the protein at theYDYVHL motif (conserved among all cas proteins). The SRC familykinases (FYN, SRC, LCK and CRK) are recruited to the phosphorylatedsites and can phosphorylate other tyrosine residues. Ligation ofeither integrin beta-1 or B-cell antigen receptor on tonsillarB-cells and B-cell lines promotes tyrosine phosphorylation and bothintegrin and BCR-mediated tyrosine phosphorylation requires anintact actin network. In fibroblasts transformation with oncogenev-ABL results in an increase in tyrosine phosphorylation.Transiently phosphorylated following CD3 cross-linking and thisphosphorylated form binds to CRK and C3G. A mutant lacking the SH3domain is phosphorylated upon CD3 cross-linking but not uponintegrin beta-1 cross-linking. Tyrosine phosphorylation occurs uponstimulation of the G-protein coupled C1a calcitonin receptor inrabbit. Calcitonin-stimulated tyrosine phosphorylation is mediatedby calcium- and protein kinase C-dependent mechanisms and requiresthe integrity of the actin cytoskeleton. Similarity: Belongs to the CAS family. Contains 1 SH3 domain. Database links: Entrez Gene: 4739 Human Entrez Gene: 18003 Mouse Omim: 602265 Human SwissProt: Q14511 Human SwissProt: O35177 Mouse Unigene: 37982 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
